Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
Closed Posted
- Opportunity number
- RFA-CA-25-004
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Up to $300,000
Opportunity facts
- Assistance listings
- Funding instrument
- Grant
- Categories
-
- Education
- Health
- Eligible applicants
-
- City/Township Governments
- State Governments
- Public or Indian Housing Auth.
- Special District Governments
- Higher Education Inst. (Public)
- For Profit Organizations
- Independent School Districts
- Higher Education Inst. (Private)
- Other
- Non-501(c)(3) Nonprofits
- Small Businesses
- County Governments
- Tribal Governments (Federally Recognized)
- Tribal Organizations (Not Federally Recognized)
- 501(c)(3) Nonprofits
- Points of contact
-
- NIH OER Webmaster grantsinfo@nih.gov
- Full announcement
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Cancer Institute (NCI) is soliciting grant applications for the development and validation of emerging biospecimen science technologies for cancer research. This funding opportunity seeks tools, devices, assays, and methods that improve the collection, handling, processing, preservation, and storage of cancer-related biospecimens. Applicants must demonstrate that major feasibility gaps have already been addressed through preliminary data, with the current project focused on further development and rigorous validation. The technologies should have potential to accelerate research in cancer biology, early detection, screening, clinical diagnosis, treatment, or epidemiology, with a particular emphasis on addressing cancer health disparities. Eligible applicants include city and state governments, public and private higher education institutions, nonprofits, small businesses, tribal organizations, and for-profit entities. The application deadline is December 9, 2025, and proposals will be evaluated based on scientific merit, technological innovation, and potential impact on cancer research.
While specific award amounts are not detailed in the grant opportunity, the funding is part of the NCI's Innovative Molecular Analysis Technologies (IMAT) Program under the Cancer Detection and Diagnosis Research grant program (CFDA 93.394). The project is expected to support research that develops advanced technologies for biospecimen handling, with a focus on preserving sample integrity and establishing quality assessment criteria. The research will be conducted at the recipient's facilities, with an anticipated project period typical of NIH grants, which generally range from 2-5 years. The ultimate goal is to create tools that can significantly improve the quality and reliability of biospecimens used in cancer research and clinical care.
Synopsis
2 versions
Update #2 · Latest ·
Through this Notice of Funding Opportunity (NOFO), National Cancer Institute (NCI) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality and handling of samples used for cancer research or clinical care. Through this NOFO, NCI will support the development of tools, devices, assays, and associated methods for the collection, handling, processing, preservation, or storage of cancer-relevant biospecimens and their derivatives. This includes tools with new capabilities to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and address issues related to pre-analytical degradation of of targeted analytes. Major feasibility gaps for the technology or methodology should have already been overcome, as demonstrated by supportive preliminary data, but the tool requires further development and rigorous validation. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, or epidemiology and/or address issues associated with cancer health disparities.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Update #1 ·
Through this Notice of Funding Opportunity (NOFO), National Cancer Institute (NCI) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality and handling of samples used for cancer research or clinical care. Through this NOFO, NCI will support the development of tools, devices, assays, and associated methods for the collection, handling, processing, preservation, or storage of cancer-relevant biospecimens and their derivatives. This includes tools with new capabilities to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and address issues related to pre-analytical degradation of of targeted analytes. Major feasibility gaps for the technology or methodology should have already been overcome, as demonstrated by supportive preliminary data, but the tool requires further development and rigorous validation. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, or epidemiology and/or address issues associated with cancer health disparities. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Files
| File | Type | Posted |
|---|---|---|
| RFA-CA-25-004-Full-Announcement.html | HTML file |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity